The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global HIV drugs market reached a value of US$ 26.4 Billion in 2020.
According to the estimates by IMARC Group, the global HIV drugs market is expected to exhibit moderate growth during the next five years.
The increasing prevalence of HIV and its diagnosis represents one of the key drivers for the global HIV drugs market.
The introduction of generic drugs that are cost-effective and chemically-identical to branded drugs represents one of the key trends in the global HIV drugs market.
Sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations and state of emergency across several nations resulting in disrupted supply chains for HIV drugs.
On the basis of the class, the market has been bifurcated into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist, and HIV integrase strand transfer inhibitors. Amongst these, nucleoside reverse transcriptase inhibitors hold the majority of the total market share.
On the basis of the distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, online pharmacies, and others. At present, hospital pharmacies exhibit a clear dominance in the market.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at